Bone disease in prostate cancer.
作者信息
Nagrial Adnan, Horvath Lisa
出版信息
Asia Pac J Clin Oncol. 2010 Mar;6(1):3-4. doi: 10.1111/j.1743-7563.2010.01281.x.
Abstract
摘要
相似文献
1
Bone disease in prostate cancer.
Asia Pac J Clin Oncol. 2010 Mar;6(1):3-4. doi: 10.1111/j.1743-7563.2010.01281.x.
2
Zometa in the treatment of diseminated prostate cancer.
Acta Chir Iugosl. 2005;52(4):119-21. doi: 10.2298/aci0504119d.
3
Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Expert Rev Anticancer Ther. 2009 Sep;9(9):1211-8. doi: 10.1586/era.09.95.
4
Words of Wisdom. Re: Randomized Controlled Trial of Early Zoledronic Acid in Men with Castration-sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
Eur Urol. 2016 Apr;69(4):754-5. doi: 10.1016/j.eururo.2016.01.019. Epub 2016 Feb 18.
5
Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?
J Clin Oncol. 2014 Nov 10;32(32):3684-5. doi: 10.1200/JCO.2014.56.2017. Epub 2014 Sep 15.
6
Reply to F. Valcamonico et al.
J Clin Oncol. 2014 Nov 10;32(32):3685. doi: 10.1200/JCO.2014.57.3808. Epub 2014 Sep 15.
7
[Zoledronic acid and osseous pathologies in the course of neoplasia. Part II].
Tumori. 2005 Nov-Dec;91(6):suppl 23-7.
8
[The role of bisphosphonate in the treatment of bone metastases from prostate cancer].
Tunis Med. 2012 Jul;90(7):507-11.
9
Unravelling the role of denosumab in prostate cancer.
Lancet. 2011 Mar 5;377(9768):785-6. doi: 10.1016/S0140-6736(11)60100-1. Epub 2011 Feb 25.
10
[Zoledronic acid and bone pathology in the course of neoplasia. Part I].
Tumori. 2005 Sep-Oct;91(5):22-6. doi: 10.1177/030089160509100524.
Zotero 插件